The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity

Objective. To evaluate the influence of combined therapy of sitagliptin and metformin on fat metabolism in patients with type 2 diabetes mellitus.Methods. The study included 82 patients (age, 55.3±9.1 years) with obesity and lipid metabolism disorders. None of the patients had reached their target g...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aleksander Sergeevich Ametov, Dinara Gadgimagomedovna Gusenbekova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2015
Materias:	sitagliptin visceral fat fat metabolism type 2 diabetes Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/b13f9ca0f1714b428c8f9802849ce023
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b13f9ca0f1714b428c8f9802849ce023
record_format	dspace
spelling	oai:doaj.org-article:b13f9ca0f1714b428c8f9802849ce0232021-11-14T09:00:20ZThe role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity2072-03512072-037810.14341/DM2015385-92https://doaj.org/article/b13f9ca0f1714b428c8f9802849ce0232015-10-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6969https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Objective. To evaluate the influence of combined therapy of sitagliptin and metformin on fat metabolism in patients with type 2 diabetes mellitus.Methods. The study included 82 patients (age, 55.3±9.1 years) with obesity and lipid metabolism disorders. None of the patients had reached their target glycated haemoglobin levels after metformin and diet therapy. Patients in group 1 (n=42) received 1.5–2-g metformin daily before the study and were switched to a formulation of 100-mg sitagliptin and 2-g metformin once a day. Patients in group 2 (n=40) were on a diet therapy before inclusion and were started on 2-g metformin/day. The following were evaluated at baseline and after 6 months of therapy: fasting glucose levels, postprandial glucose levels, glycated haemoglobin, weight, body mass index, waist circumference and lipid profile; insulin, proinsulin, leptin and adiponectin levels; insulin resistance using the homeostatic model assessment (HOMA) of β-cell function (HOMA-β) and insulin resistance (HOMA-IR). In addition, magnetic resonance imaging was performed to assess the amount of visceral fat for the total cohort.Results. After 6 months, glycated haemoglobin decreased by 18.52% (p <0.001) in group 1 and by 8.17% (p <0.001) in group 2. Fasting plasma glucose and postprandial glucose levels in group 1 were reduced by 21% (p <0.001) and 26.35% (p <0.001), respectively; the corresponding reductions in group 2 were 1.45% (p >0.05) and 5.31% (p <0.05), respectively. HOMA-β increased by 33% in group 1 (p <0.001) and by 11% in group 2 (p >0.05). Adiponectin levels increased by 27.06% (p <0.001) in group 1 and by 7.16% in group 2 (p <0.001). Leptin levels were reduced by 30.47% (p <0.001) in group 1 and by 5.41% in group 2 (p <0.001). Magnetic resonance imaging showed a 7.52% reduction in visceral fat for group 1 (p <0.001) and a 1.76% reduction for group 2 (p <0.01). The comparison of subcutaneous fat dynamics did not show statistically significant differences between the groups.Conclusion. Compared with metformin monotherapy, sitagliptin and metformin combination therapy had a prominent effect on non-glycaemic parameters, with more marked decreases in visceral fat and leptin and increases in adiponectin levels.Aleksander Sergeevich AmetovDinara Gadgimagomedovna GusenbekovaEndocrinology Research Centrearticlesitagliptinvisceral fatfat metabolismtype 2 diabetesNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 18, Iss 3, Pp 85-92 (2015)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	sitagliptin visceral fat fat metabolism type 2 diabetes Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	sitagliptin visceral fat fat metabolism type 2 diabetes Nutritional diseases. Deficiency diseases RC620-627 Aleksander Sergeevich Ametov Dinara Gadgimagomedovna Gusenbekova The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
description	Objective. To evaluate the influence of combined therapy of sitagliptin and metformin on fat metabolism in patients with type 2 diabetes mellitus.Methods. The study included 82 patients (age, 55.3±9.1 years) with obesity and lipid metabolism disorders. None of the patients had reached their target glycated haemoglobin levels after metformin and diet therapy. Patients in group 1 (n=42) received 1.5–2-g metformin daily before the study and were switched to a formulation of 100-mg sitagliptin and 2-g metformin once a day. Patients in group 2 (n=40) were on a diet therapy before inclusion and were started on 2-g metformin/day. The following were evaluated at baseline and after 6 months of therapy: fasting glucose levels, postprandial glucose levels, glycated haemoglobin, weight, body mass index, waist circumference and lipid profile; insulin, proinsulin, leptin and adiponectin levels; insulin resistance using the homeostatic model assessment (HOMA) of β-cell function (HOMA-β) and insulin resistance (HOMA-IR). In addition, magnetic resonance imaging was performed to assess the amount of visceral fat for the total cohort.Results. After 6 months, glycated haemoglobin decreased by 18.52% (p <0.001) in group 1 and by 8.17% (p <0.001) in group 2. Fasting plasma glucose and postprandial glucose levels in group 1 were reduced by 21% (p <0.001) and 26.35% (p <0.001), respectively; the corresponding reductions in group 2 were 1.45% (p >0.05) and 5.31% (p <0.05), respectively. HOMA-β increased by 33% in group 1 (p <0.001) and by 11% in group 2 (p >0.05). Adiponectin levels increased by 27.06% (p <0.001) in group 1 and by 7.16% in group 2 (p <0.001). Leptin levels were reduced by 30.47% (p <0.001) in group 1 and by 5.41% in group 2 (p <0.001). Magnetic resonance imaging showed a 7.52% reduction in visceral fat for group 1 (p <0.001) and a 1.76% reduction for group 2 (p <0.01). The comparison of subcutaneous fat dynamics did not show statistically significant differences between the groups.Conclusion. Compared with metformin monotherapy, sitagliptin and metformin combination therapy had a prominent effect on non-glycaemic parameters, with more marked decreases in visceral fat and leptin and increases in adiponectin levels.
format	article
author	Aleksander Sergeevich Ametov Dinara Gadgimagomedovna Gusenbekova
author_facet	Aleksander Sergeevich Ametov Dinara Gadgimagomedovna Gusenbekova
author_sort	Aleksander Sergeevich Ametov
title	The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
title_short	The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
title_full	The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
title_fullStr	The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
title_full_unstemmed	The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
title_sort	role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
publisher	Endocrinology Research Centre
publishDate	2015
url	https://doaj.org/article/b13f9ca0f1714b428c8f9802849ce023
work_keys_str_mv	AT aleksandersergeevichametov theroleofdipeptidylpeptidase4inhibitorsinfatmetabolisminpatientswithtype2diabetesandobesity AT dinaragadgimagomedovnagusenbekova theroleofdipeptidylpeptidase4inhibitorsinfatmetabolisminpatientswithtype2diabetesandobesity AT aleksandersergeevichametov roleofdipeptidylpeptidase4inhibitorsinfatmetabolisminpatientswithtype2diabetesandobesity AT dinaragadgimagomedovnagusenbekova roleofdipeptidylpeptidase4inhibitorsinfatmetabolisminpatientswithtype2diabetesandobesity
_version_	1718429550489108480

The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity

Ejemplares similares